KATHLEEN LINKE: Open Payments
NPI 1265883649 · HEMET, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,180 in 93 payments from 16 companies in 2025. Trend: 2023 $1,919 · 2024 $1,732 · 2025 $2,180
Food & beverage: $2,126Education: $54
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $575 |
| Madrigal Pharmaceuticals | 7 | $367 |
| Janssen Biotech, Inc. | 12 | $278 |
| PFIZER INC. | 8 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $158 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $113 |
| Gilead Sciences, Inc. | 4 | $97 |
| Enterra Medical, Inc. | 1 | $81 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| VIVUS LLC | 3 | $57 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, SKYRIZI, XELJANZ, ENTYVIO, XIFAXAN, DUPIXENT.
Industry payments across CA — which companies pay providers there.
